| | Acute Renal Failure Due to a Primary Renal B-Cell LymphomaReceived 13 March 2007; accepted 7 August 2007. published online 08 October 2007. Primary renal lymphoma (PRL) is a rare entity in which lymphoma originates in the renal parenchyma and does not represent involvement of the kidney from extrarenal disease.1 PRL presenting as acute renal failure is an even rarer entity. Because there are few cases, optimal therapy is unknown; however, generally poor renal function recovery rates and poor patient survival were reported. We report a patient who presented with acute renal failure caused by PRL with a favorable response to chemotherapy with rituximab in addition to previously reported therapy. Case Report  Clinical History A 77-year-old retired physician with a serum creatinine level of 1.0 mg/dL (88.4 μmol/L) underwent lumbosacral surgery at another institution. Three months after surgery, he was noted to have anorexia, a 20-pound weight loss, and a serum creatinine level of 4.5 mg/dL (398 μmol/L) that increased to 9.8 mg/dL (866 μmol/L) within 1 week. Ultrasonography showed his kidneys to be large (left, 13.5 cm; right, 12.5 cm) with no obstruction. The patient had no history of sicca syndrome or Sjögren disease. Because his doctors believed the anorexia and weight loss were caused by renal failure, he started dialysis therapy and then was discharged to a nursing facility. Because of continued anorexia and weakness, he was transferred to our hospital for additional examination and treatment. Physical examination on admission showed blood pressure of 154/86 mm Hg, but otherwise normal vital signs. No lymphadenopathy or edema was identified, and no abnormality was noted on physical examination other than the healed lumbosacral scar. Admission laboratory studies showed the following values: hemoglobin, 11.6 g/dL (116 g/L); leukocytes, 7,600/μL; serum creatinine, 7.3 mg/dL (645 μmol/L); normal electrolytes with corrected serum calcium of 9.3 mg/dL (2.32 mmol/L); uric acid, 2.6 mg/dL (155 μmol/L); and potassium, 5.3 mEq/L (mmol/L). A 24-hour urine measurement showed creatinine clearance of 3 mL/min (0.05 mL/s) and 880 mg of protein. Although serum protein electrophoresis showed a slight increase in γ-globulin level at 1.8 g/dL (18 g/L), no abnormal protein level was found. Sedimentation rate was 31 mm/h with a C-reactive protein level of 8.2 mg/dL. All test results for antinuclear, anti-DNA, anti–glomerular basement membrane, and antineutrophil cytoplasmic antibodies were negative, with normal complement and angiotensin-converting enzyme levels. Percutaneous biopsy of the right kidney guided by computed tomography was performed. Kidney Biopsy Light microscopic evaluation showed 2 cores of renal medulla and 2 cores of cortex with 7 glomeruli. There was moderately increased mesangial matrix with no proliferation; capillary basement membranes were unremarkable with silver stain. There was dense lymphocytic infiltration throughout the cortex (Fig 1A) and focally in the medulla, consistent with PRL. Tumor cells were large with atypical nuclear features, and numerous mitoses were noted (Fig 1B). Periodic acid-Schiff hematoxylin and trichrome stains showed tubular atrophy with no tubulitis. An immunohistochemical stain for CD20 was strongly positive in most neoplastic cells throughout the cortex and focally in the medulla (Fig 2A). Staining for CD3 showed only occasional cells with positive staining (Fig 2B). Immunofluorescence sections contained 3 glomeruli. There was diffuse 1+ mesangial staining for C3, but stains for immunoglobulin G, immunoglobulin M, immunoglobulin A, C1q, and light chains were negative. There was 2+ staining for C3 in vessels and focally in tubular basement membranes. Ultrastructural examination confirmed marked expansion of the interstitium by tumor cells. Nuclei were irregularly shaped with dispersed chromatin and 1 or more small nucleoli. There were relatively few organelles; scattered mitochondria and rare lysosomes were noted. No intercellular junctions were identified. Diagnosis The final diagnosis was poorly differentiated large B-cell lymphoma. Clinical Follow-Up The patient underwent an extensive search for extrarenal lymphoma. Additional computed tomography of the chest, head, abdomen, and pelvis showed a 2-cm mass in the right kidney that was believed to be a more localized area of the lymphoma (Fig 3), with no evidence of hematoma from the biopsy. However, no lymphadenopathy or other organ involvement was identified. The diagnosis was PRL with no extrarenal involvement. The patient began treatment with cyclophosphamide (1,000 mg intravenously), vincristine (2 mg intravenously), prednisone (80 mg/d for 5 days), and rituximab (675 mg intravenously). Within 1 week, urine output improved, with a serum creatinine level of only 2.6 mg/dL (230 μmol/L) and an estimated glomerular filtration rate by means of the Modification of Diet in Renal Disease Study equation of 26 mL/min/1.73 m2 (0.43 mL/s/1.73 m2). Six months after initiation of chemotherapy, he remained free of dialysis therapy, had a serum creatinine level of 2.4 mg/dL (212 μmol/L), gained 15 pounds, and was considered to be in remission. Discussion  PRL as a clinical entity has been disputed because the kidneys do not contain lymphatic tissue and the mechanism of development of PRL is unclear.2, 3 The diagnosis should be made only in the absence of extrarenal lymphoma, paraproteinemia, and leukemic blood phase.4 Most of the few reported cases showed rapid progression and a poor prognosis, with a 1-year mortality rate of 75%.5 Histologically, most cases showed a diffuse pattern of proliferation, with B-cell type shown on immunohistochemistry.4 Etiologic factors for PRL are unknown. Several decades ago, low-grade B-cell lymphomas of mucosa-associated lymphoid tissue were shown to arise in nonlymphoid tissue because of chronic inflammation.6, 7, 8, 9, 10 However, renal mucosa-associated lymphoid tissue is uncommon.11, 12 Although 1 case of an immunoblastic lymphoma with human immunodeficiency virus infection13 and 1 case of the African form of Burkitt lymphoma14 were reported as PRL, there is no evidence that chronic inflammation usually induces PRL. All attempts to find a linkage of PRL to such chronic inflammation as chronic pyelonephritis,1 Sjögren syndrome,1 systemic lupus erythematosus,1 or Epstein-Barr virus have failed.3 Acute renal failure caused by PRL is extremely rare. As of 2004, only 11 patients with PRL presenting as acute renal failure were reported,15 and since then, only 2 additional patients were reported,14, 16 whereas 7 other patients with ARF caused by lymphomatous infiltration either had extrarenal lymphoma14, 17, 18, 19 or leukemia18 and thus did not meet criteria for PRL. In our patient, we found no cause other than PRL for impaired renal function. Pathophysiological characteristics of acute renal failure in patients with PRL are believed to be caused by tubular compression and impairment of renal parenchymal blood flow,2 which might be expected from the massive lymphocytic infiltration noted in our patient. The rapid improvement in renal function that our patient experienced after treatment of his lymphoma suggests that PRL was the cause of his dysfunction. Because involvement of 1 kidney should not have resulted in renal failure, our patient most likely had bilateral involvement, although the biopsy was only from the right kidney. There is no standard treatment for patients with PRL because the number of reported cases remains small. Although the most common treatment is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP),1, 2, 15, 18, 20 various other chemotherapeutic agents were tried.5, 15, 16, 20 However, to our knowledge, this is the first time rituximab has been added. Rituximab is a chimeric monoclonal antibody against CD20, which is a surface antigen on both normal and neoplastic B lymphocytes. Although it was not previously used in patients with PRL, in those with other B-cell lymphomas, the addition of rituximab was associated with significantly better complete response and overall survival.21 Although survival in patients with untreated PRL is often days, with no recovery of renal function,15 chemotherapy has increased survival. One patient was able to experience a remission after chemotherapy and nephrectomy,2 whereas another recovered renal function within a month of treatment with CHOP.16 It is difficult to make generalizations; however, the course of our patient suggests that rituximab might be a useful addition to the chemotherapeutic regimen. Acknowledgements  Support: None. Financial Disclosure: None. References  1. 1Brouland JP, Meeus F, Rossert J, et al. Primary bilateral B-cell renal lymphoma: A case report and review of the literature. Am J Kidney Dis. 1994;24:586–589. Abstract 2. 2Gellrich J, Hakenberg OW, Naumann R, Manseck A, Lossnitzer A, Wirth MP. Primary renal non-Hodgkin’s lymphoma—A difficult differential diagnosis. Onkologie. 2002;25:273–277.
CrossRef
3. 3Stallone G, Infante B, Manno C, Campobasso N, Pannarale G, Schena FP. Primary renal lymphoma does exist: Case report and review of the literature. J Nephrol. 2000;13:367–372. MEDLINE 4. 4Yasunaga Y, Hoshida Y, Hashimoto M, Miki T, Okuyama A, Aozasa K. Malignant lymphoma of the kidney. J Surg Oncol. 1997;64:207–211. MEDLINE |
CrossRef
5. 5Porcaro AB, D’Amico A, Novella G, et al. Primary lymphoma of the kidney (Report of a case and update of the literature). Arch Ital Urol Androl. 2002;74:44–47. MEDLINE 6. 6Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer. 1984;53:2515–2524. 7. 7Hyjek E, Isaacson PG. Primary B cell lymphoma of the thyroid and its relationship to Hashimoto’s thyroiditis. Hum Pathol. 1988;19:1315–1326. MEDLINE |
CrossRef
8. 8Hyjek E, Smith WJ, Isaacson PG. Primary B-cell lymphoma of salivary glands and its relationship to myoepithelial sialadenitis. Hum Pathol. 1988;19:766–776. MEDLINE |
CrossRef
9. 9Wundisch T, Mosch C, Neubauer A, Stolte M. Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: Results of a 196-patient series. Leuk Lymphoma. 2006;47:2110–2114. MEDLINE |
CrossRef
10. 10Cortot AB, Cottin V, Issartel B, Meyronet D, Coiffier B, Cordier JF. Pulmonary MALT lymphoma revealing AIDS. Rev Mal Respir. 2006;23:353–357. MEDLINE |
CrossRef
11. 11Parveen T, Navarro-Roman L, Medeiros LJ, Raffeld M, Jaffe ES. Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue arising in the kidney. Arch Pathol Lab Med. 1993;117:780–783. MEDLINE 12. 12Jindal B, Sharma SC, Das A, Banerjee AK. Indolent behaviour of low-grade B cell lymphoma of mucosa-associated lymphoid tissue arising in the kidney. Urol Int. 2001;67:91–93. MEDLINE |
CrossRef
13. 13Tsang K, Kneafsey P, Gill MJ. Primary lymphoma of the kidney in the acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1993;117:541–543. MEDLINE 14. 14Olowu WA, Adelusola KA, Badmos KB, Aina OJ. Autopsy diagnosis of endemic Burkitt lymphoma as the primary etiology of acute renal failure in children. Pediatr Hematol Oncol. 2005;22:315–321. MEDLINE |
CrossRef
15. 15Sellin L, Friedl C, Klein G, Waldherr R, Rump LC, Weiner SM. Acute renal failure due to a malignant lymphoma infiltration uncovered by renal biopsy. Nephrol Dial Transplant. 2004;19:2657–2660. MEDLINE |
CrossRef
16. 16Omer HA, Hussein MR. Primary renal lymphoma. Nephrology. 2007;12:314–315. MEDLINE |
CrossRef
17. 17Harzallah K, Laadidi J, Chatti K, et al. Acute renal failure due to lymphomatous infiltration: An unusual presentation. Saudi J Kidney Dis Transpl. 2006;17:395–398. MEDLINE 18. 18Lommatzsch SE, Bellizzi AM, Cathro HP, Rosner MH. Acute renal failure caused by renal infiltration by hematolymphoid malignancy. Ann Diagn Pathol. 2006;10:230–234. Abstract | Full Text |
Full-Text PDF (353 KB)
|
CrossRef
19. 19Colak N, Dede F, Canbakan B, Odabas AR, Akyurek N. Acute tubulo-interstitial nephritis associated with mantle cell lymphoma presented as acute renal failure. Nephrology. 2007;12:107–108. MEDLINE |
CrossRef
20. 20Simsek S, Oen AL, Comans EF, v d Hoeven JJ, Zijlstra J. Acute renal failure due to non-Hodgkin lymphoma infiltration of the kidneys detected by ultrasonography and confirmed by positron emission tomography. Clin Nephrol. 2003;59:383–387. MEDLINE 21. 21Coiffier B. Monoclonal antibody as therapy for malignant lymphomas. C R Biol. 2006;329:241–254. MEDLINE |
CrossRef
1 Hypertension, Nephrology, Dialysis and Transplantation Clinic, Auburn University, Auburn 2 Internal Medicine Clinic, Opelika, University of Alabama at Birmingham, Birmingham, AL 3 Department of Pathology, University of Alabama at Birmingham, Birmingham, AL. Address correspondence to Charles J. Diskin, MD, Hypertension, Nephrology, Dialysis & Transplantation, Bldg 21, 121 North 20th St, Opelika, AL 36801.
PII: S0272-6386(07)01144-4 doi:10.1053/j.ajkd.2007.08.008 © 2007 National Kidney Foundation, Inc. Published by Elsevier Inc All rights reserved. | |
|